Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for Delirium in Critically Ill Patients
NCT04578886Phase 3Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of guanfacine in delirium, sponsored by University of Alabama at Birmingham. Primary endpoint: Days Without Delirium at 14 days. Started Nov 2020; status: completed.
02
Drugs
guanfacine
03
Conditions
delirium
Beyond the preview
Go deeper on NCT04578886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578886.